PRIMAQUINE 7.5 TAB is a potent and essential antimalarial formulation containing Primaquine Phosphate 7.5 mg per tablet. Primaquine is a synthetic 8-aminoquinoline compound known for its unique mechanism of action in targeting the dormant hepatic stages (hypnozoites) of malaria parasites, specifically Plasmodium vivax and Plasmodium ovale. This property allows it to provide a radical cure by preventing malaria relapses, a crucial step in malaria elimination efforts, especially in endemic regions.
The 7.5 mg strength of Primaquine is particularly useful for flexible dosing regimens, especially in pediatric cases, elderly patients, or those with lower body weight, where higher doses may not be appropriate. It also allows healthcare providers to titrate treatment more precisely in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or other contraindications where lower dosage thresholds are necessary for safety.
Apart from its action on P. vivax and P. ovale, PRIMAQUINE 7.5 TAB also serves a key role in reducing malaria transmission by targeting the gametocytes of Plasmodium falciparum, the sexual form of the parasite that is responsible for infecting mosquitoes and perpetuating the malaria cycle. By clearing these gametocytes, Primaquine acts as a transmission-blocking agent, supporting broader public health efforts during outbreaks and mass drug administration campaigns.
While the exact mechanism of action remains under investigation, Primaquine is believed to interfere with mitochondrial electron transport in the parasite, generating oxidative stress that leads to its death. It is not effective against the asexual blood stages of the parasite and is therefore usually used in combination with a schizonticidal drug such as chloroquine, artemether-lumefantrine, or other ACTs (Artemisinin-based Combination Therapies).
Administration of PRIMAQUINE 7.5 TAB is typically carried out over a 14-day course, depending on treatment objectives, patient weight, and regional guidelines. Before initiating therapy, testing for G6PD deficiency is strongly advised. In G6PD-deficient individuals, Primaquine can induce hemolytic anemia, so alternative regimens or close clinical monitoring is required.
Side effects associated with Primaquine 7.5 mg are generally mild but may include gastrointestinal disturbances like nausea, vomiting, abdominal cramps, and headache. More severe adverse events like methemoglobinemia or hemolytic anemia are rare and dose-dependent. Regular hematological assessments during the course of therapy are often recommended, particularly for vulnerable populations.
PRIMAQUINE 7.5 TAB is an essential medicine in the arsenal of global health organizations, NGOs, and government malaria programs. Its strategic use is advocated by the World Health Organization (WHO) in settings aiming for malaria control, elimination, or eradication. Bluepill Express ensures that this product is manufactured in WHO-GMP certified units with strict adherence to quality control, international packaging standards, and regulatory compliance.
Each batch of PRIMAQUINE 7.5 TAB is backed by full documentation including Certificate of Analysis (COA), stability data, and regulatory dossiers, making it suitable for international distribution across Africa, Asia, Latin America, and other malaria-endemic regions. Bluepill Express offers contract manufacturing, private labeling, and export solutions tailored to client needs, whether for institutional tenders or commercial distribution.
Description provided by bluepill express.
FIEO Registered
Export Ready
